STOCK TITAN

Avadel (AVDL) director shifts 67,025 shares to charitable remainder trust

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Avadel Pharmaceuticals director Mark Anthony McCamish reported an internal share transfer involving 67,025 ordinary shares on February 4, 2026. The filing shows 67,025 shares moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust at a stated price of $0 per share.

Following these transactions, 67,025 ordinary shares are reported as indirectly held through the McCamish Charitable Remainder Trust and 22,000 ordinary shares are reported as directly held. The reporting person and his spouse are income beneficiaries of the charitable remainder trust, and he disclaims beneficial ownership except for his and his spouse's pecuniary interest.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McCamish Mark Anthony

(Last) (First) (Middle)
C/O AVADEL PHARMACEUTICALS PLC
10 EARLSFORT TERRACE

(Street)
DUBLIN 2 L2 D02 T380

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AVADEL PHARMACEUTICALS PLC [ AVDL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 02/04/2026 G(1) 67,025 D $0 0 I By Matthew 5 LLC(2)
Ordinary Shares 02/04/2026 G(1) 67,025 A $0 67,025 I By McCamish Charitable Remainder Trust(3)
Ordinary Shares 22,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On February 4, 2026, the Reporting Person transferred 67,025 shares from Matthew 5 LLC to the McCamish Charitable Remainder Trust.
2. Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
3. Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein.
/s/ Jerad G. Seurer, as Attorney-in-Fact 02/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Avadel (AVDL) director Mark McCamish report?

Avadel director Mark Anthony McCamish reported a transfer of 67,025 ordinary shares on February 4, 2026. The shares moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust at a stated price of $0 per share, reflecting a non-cash internal reallocation.

How many Avadel (AVDL) shares were transferred between Matthew 5 LLC and the charitable trust?

The filing shows that 67,025 Avadel ordinary shares were transferred on February 4, 2026. These shares moved from Matthew 5 LLC to the McCamish Charitable Remainder Trust, with both legs reported at a transaction price of $0 per share as an internal transfer.

What are Mark McCamish’s Avadel (AVDL) share holdings after this Form 4?

After the reported transactions, 67,025 Avadel ordinary shares are indirectly held through the McCamish Charitable Remainder Trust, and 22,000 ordinary shares are listed as directly held. The filing also notes the reporting person’s indirect involvement through related entities and his pecuniary interest in the trust.

How is Matthew 5 LLC related to Avadel (AVDL) director Mark McCamish?

Shares previously held by Matthew 5 LLC are described as owned by an entity whose sole owner is the Mark & Barbara McCamish Family Trust. The Form 4 states that Mark Anthony McCamish serves as the manager of Matthew 5 LLC in connection with these indirectly held Avadel shares.

What does the Form 4 say about McCamish’s beneficial ownership of Avadel (AVDL) shares in the trust?

The Form 4 explains that shares are held by the McCamish Charitable Remainder Trust, where the reporting person and his spouse are income beneficiaries. It also states he disclaims beneficial ownership of those Avadel shares except to the extent of his and his spouse’s pecuniary interest.
Avadel Pharmaceu

NASDAQ:AVDL

AVDL Rankings

AVDL Latest News

AVDL Latest SEC Filings

AVDL Stock Data

2.12B
97.12M
4.89%
86.45%
10.8%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2